BR112021018801A2 - Métodos para tratar a distrofia muscular com casimersen - Google Patents

Métodos para tratar a distrofia muscular com casimersen

Info

Publication number
BR112021018801A2
BR112021018801A2 BR112021018801A BR112021018801A BR112021018801A2 BR 112021018801 A2 BR112021018801 A2 BR 112021018801A2 BR 112021018801 A BR112021018801 A BR 112021018801A BR 112021018801 A BR112021018801 A BR 112021018801A BR 112021018801 A2 BR112021018801 A2 BR 112021018801A2
Authority
BR
Brazil
Prior art keywords
methods
muscular dystrophy
casimersen
treating muscular
treating
Prior art date
Application number
BR112021018801A
Other languages
English (en)
Inventor
M Kaye Edward
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Publication of BR112021018801A2 publication Critical patent/BR112021018801A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

métodos para tratar a distrofia muscular com casimersen. a presente invenção fornece, entre outras coisas, composições e métodos aprimorados para tratar a distrofia muscular. por exemplo, presente invenção fornece métodos para tratar pacientes com distrofia muscular de duchenne com uma mutação no gene dmd que é suscetível a skipping do éxon 45 pela administração de uma quantidade eficaz de casimersen.
BR112021018801A 2019-03-28 2020-03-25 Métodos para tratar a distrofia muscular com casimersen BR112021018801A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962825573P 2019-03-28 2019-03-28
US201962902518P 2019-09-19 2019-09-19
PCT/US2020/024550 WO2020198268A1 (en) 2019-03-28 2020-03-25 Methods for treating muscular dystrophy with casimersen

Publications (1)

Publication Number Publication Date
BR112021018801A2 true BR112021018801A2 (pt) 2021-11-23

Family

ID=70286009

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021018801A BR112021018801A2 (pt) 2019-03-28 2020-03-25 Métodos para tratar a distrofia muscular com casimersen

Country Status (15)

Country Link
US (1) US20220152086A1 (pt)
EP (1) EP3946376A1 (pt)
JP (1) JP2022526763A (pt)
KR (1) KR20210145192A (pt)
CN (1) CN113660939A (pt)
AU (1) AU2020244803A1 (pt)
BR (1) BR112021018801A2 (pt)
CA (1) CA3134165A1 (pt)
CL (1) CL2021002437A1 (pt)
CO (1) CO2021014024A2 (pt)
IL (1) IL286653A (pt)
MA (1) MA55515A (pt)
MX (1) MX2021011498A (pt)
SG (1) SG11202108757XA (pt)
WO (1) WO2020198268A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021025899A1 (en) * 2019-08-02 2021-02-11 Sarepta Therapeutics, Inc. Phosphorodiamidate morpholino oligomer pharmaceutical compositions
WO2023168427A1 (en) 2022-03-03 2023-09-07 Yale University Compositions and methods for delivering therapeutic polynucleotides for exon skipping

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445129A (fr) 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3453257A (en) 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3453259A (en) 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
DE3650699T2 (de) 1985-03-15 1999-04-15 Antivirals Inc Immunotestmittel für Polynukleotid und Verfahren
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
CA2140343A1 (en) 1992-07-17 1994-02-03 Sean M. Sullivan Method and reagent for treatment of animal diseases
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
WO1999042091A2 (en) 1998-02-19 1999-08-26 Massachusetts Institute Of Technology Use of polycations as endosomolytic agents
WO2001047496A1 (en) 1999-12-29 2001-07-05 Mixson A James Histidine copolymer and methods for using same
US7070807B2 (en) 1999-12-29 2006-07-04 Mixson A James Branched histidine copolymers and methods for using same
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
CN109311919A (zh) * 2016-06-30 2019-02-05 萨勒普塔医疗公司 用于肌肉萎缩症的外显子跳跃寡聚体
DK4122497T3 (da) * 2016-12-19 2024-06-10 Sarepta Therapeutics Inc Exonskipping-oligomerkonjugater til muskeldystrofi
JP2020536058A (ja) * 2017-09-28 2020-12-10 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィーを処置するための併用療法

Also Published As

Publication number Publication date
MX2021011498A (es) 2022-01-04
SG11202108757XA (en) 2021-10-28
WO2020198268A1 (en) 2020-10-01
CO2021014024A2 (es) 2021-10-29
CN113660939A (zh) 2021-11-16
JP2022526763A (ja) 2022-05-26
IL286653A (en) 2021-10-31
KR20210145192A (ko) 2021-12-01
CL2021002437A1 (es) 2022-05-06
EP3946376A1 (en) 2022-02-09
US20220152086A1 (en) 2022-05-19
AU2020244803A1 (en) 2021-11-18
MA55515A (fr) 2022-02-09
CA3134165A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
BR112018006445A2 (pt) métodos para tratar distrofia muscular
CO2020004034A2 (es) Métodos para el tratamiento de distrofia muscular
BR112018009235A8 (pt) composição de aditivo alimentar
BR112022012594A2 (pt) Dosagem de gama-hidroxibutirato (ghb)
BR112018008358A2 (pt) ?composições e métodos para terapia relacionada à microbiota fecal?
BR112021018801A2 (pt) Métodos para tratar a distrofia muscular com casimersen
BR112017005767A2 (pt) composições de limpeza contendo uma polieteramina
CO2020012060A2 (es) Inhibidores de la arginasa
BR112022007677A2 (pt) L-asparaginase recombinante
BR112016030434A8 (pt) formulação de látex para produzir produtos elastoméricos
BR112015029144A2 (pt) formulações de gel para guiar radioterapia
BR112017010132A2 (pt) terapia combinada para tratamento de infecções bacterianas resistentes
CO2021001472A2 (es) Inhibidores de transglutaminasa 2 (tg2)
BR112022010323A2 (pt) Composto, composto ou sal, medicamento, métodos para ativar um receptor tipo 2 de orexina e para prevenir ou tratar narcolepsia, e, uso do composto ou sal
BR112017007817A2 (pt) tratamento do câncer com estimuladores imunológicos
BR112013027789A2 (pt) processo para produzir misturas de borracha
BR112018070060A2 (pt) composições para tratamento bucal com uma exibição de sabor eficiente
MX2019002284A (es) Sistemas de deposito que comprenden acetato de glatiramer.
BR112019002458A2 (pt) composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos
BR112017016378A2 (pt) composições da pró-droga de fumarato de monometila
MX2020012497A (es) Moduladores de la expresion de apol1.
BR112021024109A2 (pt) Composições farmacêuticas compreendendo um agonista fxr e um fibrato para uso no tratamento de doença hepática colestática
BR112017015613A2 (pt) gel intestinal de levodopa e carbidopa e métodos de utilização
AR118495A1 (es) Métodos para tratar la distrofia muscular
PH12020550526A1 (en) Edasalonexent dosing regimen for treating muscular dystrophy